ESTRO 2024 - Abstract Book

S1770

Clinical - Lung

ESTRO 2024

Each patient enrolled in this study underwent a follow-up of at least six months (6-36 months). At the study end (may 2023), 5 patients were alive and 2 of them had no recurrence. After SABR treatment, 9 patients underwent systemic therapy for disease progression (3 for extensive local progression and 6 for distant progression). The retreatment with SABR was well tolerated by all the patients. At the end of SABR treatment, one case of G2 asthenia associated with G1 cough, two cases of G1 dyspnea and one case of G1 gastrointestinal toxicity (nausea and vomiting) were recorded. In all other cases, the clinical conditions of the patients were observed to be stable respect to the late toxicity (>6 months from the conclusion) of the radical radiation treatment (5 cases of G2 dyspnoea, one case of G1 rib chest pain and one case of pericarditis). The median calculated TFST is 10.2 months [Q1-Q3: 4.8-17.1]. OS at 6 months was 95.2% [70.7%-99.3%], at 12 months: 56.4% [32.8%-74.5%] at 36 months 27.4% [9.5%- 48%]. As regards PFS at 6 months it was 71.8% [47.6%- 86.2%], at 12 months it was 33.5% [15.0%-53.3%] and at 36 months it was 14% [3.6%-32.2%] (Figure1).

Conclusion:

Made with FlippingBook - Online Brochure Maker